Uncover key drivers, emerging technologies, and competitive movements shaping the calcitonin gene-related peptide (cgrp) inhibitors market from 2025–2034 with trusted insights from The Business Research Company
What Is The Predicted Size Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Industry By 2029?
The calcitonin gene-related peptide (cgrp) inhibitors market has experienced robust growth recently. Projections indicate its expansion from $2.87 billion in 2024 to $3.14 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.6%. This historical expansion is largely due to escalating investments in research and development, an increase in new drug approvals, a greater need for non-opioid pain relievers, and an enhanced emphasis on personalized medicine.
The calcitonin gene-related peptide (cgrp) inhibitors market size is projected to experience robust expansion over the coming years. This market is set to reach ” $4.58 billion by 2029, achieving a compound annual growth rate (CAGR) of 9.9%. The anticipated increase during this period stems from factors such as the rising incidence of migraine, increased uptake of preventive migraine therapies, heightened patient awareness, and a surge in healthcare spending. Key developments expected within the forecast timeframe encompass advancements in drug formulation technology, the incorporation of digital health solutions, progress in precision medicine, and enhancements in biosimilar technologies.
Access A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
What Major Drivers Are Impacting The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The expanding occurrence of migraine is anticipated to drive the advancement of the calcitonin gene-related peptide (CGRP) inhibitors market in the future. Migraine refers to a severe headache characterized by pulsating pain, frequently localized to one side of the head, and commonly presents with symptoms such as nausea, emesis, and heightened sensitivity to light and sound. The heightened incidence of migraine stems from escalating stress levels, given that prolonged stress activates specific neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors contribute to migraine management through a targeted, prophylactic approach and their suitability for both acute and long-term treatment plans. These inhibitors diminish the frequency and intensity of headaches by effectively blocking CGRP receptors, thereby enhancing patient quality of life and everyday functionality. For example, data from January 2023, provided by the National Library of Medicine, a US-based health information institution, indicates that the worldwide prevalence of migraine ranges from 14% to 15%, accounting for 4.9% of the total global disease burden. Consequently, the rising occurrence of migraine is propelling the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market.
Which Segment Categories Are Driving Maximum Growth In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Which Long-Term Trends Will Play A Crucial Role In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Leading companies within the calcitonin gene-related peptide (CGRP) inhibitors market are prioritizing the creation of novel products to secure regulatory approvals. These innovations, particularly calcitonin gene-related peptide (CGRP) receptor antagonists, aim to boost migraine treatment effectiveness, broaden therapeutic applications, and introduce more user-friendly administration methods, including oral and intranasal forms. A calcitonin gene-related peptide (CGRP) receptor antagonist functions by inhibiting the calcitonin gene-related peptide (CGRP) receptor, thereby interrupting pain signals associated with migraine. As an illustration, in April 2023, the US-based biotech firm AbbVie Inc. obtained approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for the management of chronic migraine in adults. QULIPTA is an oral calcitonin gene-related peptide (CGRP) receptor antagonist, operating by obstructing calcitonin gene-related peptide (CGRP) receptors, which play a role in migraine pathophysiology, thus assisting in the prevention of migraine episodes.
Who Are The Dominant Players In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Today?
Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.
Download The Full Report Here:
Which Region Is At The Forefront Of Innovation In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get A Report Customized For You Here:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp
Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market 2025, By The Business Research Company
Her2 Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Checkpoint Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Protein Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model